Real-world use of EndoPredict to guide treatment in early HR+/HER2- breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational project uses prospectively collected data from French laboratories participating in the SiMoSein registry since 2016 to track outcomes after EndoPredict testing. Clinical, pathological, and genomic data collected include age, tumor size, lymph node status, histology, grade, HR and HER2 IHC, Ki67, EPscore, Epclin score, and estimated absolute chemotherapy benefit. Patients are followed for up to 10 years to measure relapse-free survival and overall survival. Analyses will compare outcomes by EPclin risk class, nodal status (N0/N1), tumor size (pT), and predefined age groups.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient with early breast cancer, hormone receptor-positive, HER2 non-amplified, for whom clinical criteria are deemed insufficient to determine the need for adjuvant chemotherapy, combined with hormone therapy, after breast surgery.

Exclusion Criteria:

* Patients who did not undergo testing or whose test results were not validated

Where it's running

• Hôpital Saint-Louis
  Paris, France Recruiting

Study contacts

• Study coordinator: Jacqueline LEHMANN-CHE, MD
• Email: jacqueline.lehmann-che@aphp.fr
• Phone: 01 56 09 21 11

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PRT13722 in advanced HR+/HER2- breast cancer

  This early study tests PRT13722, by itself and with standard therapies, to see if it is safe and has any signs of activity in adults with HR+/HER2- breast cancer who have progressed on prior treatments.

  Recruiting Phase 1 Prelude Therapeutics Incorporated · Maumee, Ohio · NCT07905001

• Giredestrant in ER-positive, HER2-negative early breast cancer: who tolerates it and sticks with treatment

  This study tests how well people with ER-positive, HER2-negative early breast cancer can tolerate and stay on giredestrant, and how they feel during treatment.

  Recruiting Phase 3 Hoffmann-La Roche · Québec, Quebec · NCT07827573

• Exergames-acceptance and Commitment Therapy for Breast Cancer Depression and Anxiety

  This trial tests whether a combined exergame-based program with acceptance and commitment therapy helps reduce depression and anxiety in breast cancer survivors compared with ACT alone or standard care.

  Recruiting Universiti Sains Malaysia · Xinxiang, Henan · NCT07721753

• Skipping hormone therapy for some low-risk early breast cancer patients

  This trial tests whether certain older, postmenopausal women with very small, low-risk ER-positive HER2-negative breast cancers can skip hormone therapy after surgery without raising the chance of cancer coming back.

  Recruiting at 10 sites Phase 2 Unicancer · Angers and 40 other locations · NCT07661927

• Metronomic Oral Paclitaxel for Advanced HER2-Negative Breast Cancer

  This study tests whether low, regular doses of an oral paclitaxel solution can be safely used to control tumor growth in adults with advanced HER2-negative breast cancer who have already had prior cancer therapy.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT07602907

• Polarized light therapy to reduce radiation dermatitis in breast cancer patients

  Aly randomized trial will test whether adding polarized light therapy to standard skin care can lessen radiation dermatitis in women receiving hypofractionated whole-breast radiotherapy.

  Recruiting Beni-Suef University · Banī Suwayf · NCT07600957

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.